A key sub-group from a provincial cohort of individuals impacted substance use disorder in BC. The project was developed to monitor service use, health care integration and patient outcomes in BC on a continuing basis and to provide the foundation for evaluative studies on the costs and benefits of the DTES-2GS.
STUDIES MENU
FUNDING ORGANIZATIONS
Scroll to Top
CLICK FOR GP-41 DISCONTINUATION NOTICE
The British Columbia Centre for Excellence in HIV/AIDS Laboratory has discontinued gp-41 resistance testing as T-20 (enfuvirtide/Fuzeon) is no longer available in Canada as of March 31, 2025